First human test of new lung cancer drug combo completed

NCT ID NCT06525246

Summary

This study tested the safety and side effects of a new drug, ONO-7475, when given alongside the standard drug osimertinib. It involved 78 adults with advanced or recurrent non-small cell lung cancer that has a specific genetic change (EGFR mutation). The main goal was to find a safe dose for future research, not to cure the disease.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT NON SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Hyogo College Of Medicine College Hospital

    Nishinomiya, Hyōgo, Japan

  • Kanagawa Cancer Center

    Yokohama, Kanagawa, Japan

  • Kitasato University Hospital

    Sagamihara-shi, Kanagawa, Japan

  • Kobe City Medical Center General Hospital

    Kobe, Hyōgo, Japan

  • National Hospital Organization Shikoku Cancer Center

    Matsuyama, Ehime, Japan

  • Nigata Cancer Center Hospital

    Niigata, Niigata, Japan

  • Osaka International Cancer Institute

    Osaka, Osaka, Japan

  • Osaka Medical and Pharmaceutical University Hospital

    Takatsuki, Osaka, Japan

  • Saitama Cancer Center

    Ina, Kitaadati-gun, Saitama, Japan

  • Shizuoka Cancer Center

    Nagaizumi-chō, Sunto-gun, Shizuoka, Japan

  • The Cancer Institute Hospital Of JFCR

    Koto-Ku, Tokyo, Japan

  • Tokyo Medical University Hospital

    Shinjuku-Ku, Tokyo, Japan

  • University Hospital Kyoto Prefectural University of Medicine

    Kyoto, Kyoto, Japan

Conditions

Explore the condition pages connected to this study.